










Supplemental Fig. 1. Kaplan-Meier estimates of overall survival according to treatment in miR-21 positive patients **(A)** compared with miR-21 negative patients **(B)**, in miR-29b positive patients **(C)** compared with miR-29b negative patients **(D)**, in miR-34a positive patients **(E)** compared with miR-34a negative patients **(F)**, in miR-34b positive patients **(G)** compared with miR-34b negative patients **(H)**, in miR-34c positive patients **(I)** compared with miR-34c negative patients **(J)**, in miR-155 positive patients **(K)** compared with miR-155 negative patients **(L)**, in Let-7a positive patients **(M)** compared with Let-7a negative patients **(N)**




Overall survival in miR-34c negative group by treatment




At risk	— 146	120	99	83	70	60	47	37	27
	— 163	140	119	101	91	72	52	35	24

Overall survival in miR-34c positive group by treatment




At risk	— 152	126	101	88	79	66	48	33	20
	— 157	143	120	98	85	73	60	41	28

Overall survival in miR-155 negative group by treatment




At risk	— 161	131	110	92	78	66	50	39	24
	— 157	134	106	89	75	52	43	29	21

Overall survival in miR-155 positive group by treatment




At risk	— 147	125	98	88	78	67	52	36	24
	— 172	156	138	114	104	95	70	48	32

Overall survival in Let-7a negative group by treatment



At risk	— 160	129	103	90	74	61	49	34	25
	— 159	136	111	90	76	62	46	27	19

Overall survival in Let-7a positive group by treatment



At risk	— 149	127	105	89	81	71	52	40	23
	— 170	154	133	113	103	85	67	50	34